Fragmented discovery
Products, documents and technical claims are spread across suppliers and presented in inconsistent formats.
Investment and strategic partnerships
ABMIUM is building the trust and transaction layer for life science research commerce, connecting scientists with transparent product origin, stronger evidence and a more efficient route to the right reagent.
ABMIUM is building the trust and transaction layer for life science research commerce, connecting scientists with transparent product origin, stronger evidence and a more efficient route to the right reagent.
Researchers can access enormous catalogues, yet still struggle to compare product origin, supplier role, evidence quality and application fit before purchase. The result is wasted budget, delayed experiments and avoidable uncertainty. ABMIUM is building a marketplace around the decision, not simply the listing.
Products, documents and technical claims are spread across suppliers and presented in inconsistent formats.
Manufacturer, distributor and relabeller roles are not always obvious, making provenance and accountability harder to assess.
A reagent that is wrong for the target, sample or application can cost far more than its purchase price.
ABMIUM brings product discovery, provider transparency, structured scientific information and human sourcing support into one commercial layer. Manufacturers remain visible. Researchers gain a clearer buying route. Suppliers gain qualified access to international demand.
The core transaction is product supply. Around it, ABMIUM can create value through scientific sourcing, validation pathways, institutional relationships and international supplier access. Each workflow improves the data and relationships that support the next transaction.
Commercial margin on products supplied through a multi-provider catalogue and direct-fulfilment network.
Higher-touch support for custom requirements, evidence questions and projects that do not fit a standard search.
Repeat procurement routes, international distribution and strategic programmes that deepen marketplace participation.
ABMIUM is not trying to become another private-label catalogue. The opportunity is to become the trusted infrastructure between researchers and the manufacturers that serve them.
Visible manufacturer and provider identity creates a clearer alternative to opaque relabelling.
Normalised product and evidence information makes discovery and comparison more useful over time.
Application-aware sourcing and validation support connect marketplace activity to real experimental decisions.
A multi-supplier, direct-fulfilment approach expands breadth without requiring ABMIUM to manufacture every product.
ABMIUM is an early-stage UK life science company with its marketplace, initial reagent categories, supplier relationships and scientific workflows in development and operation. The next phase is focused on commercial adoption, stronger catalogue intelligence, repeat institutional purchasing and international scale.
Antibodies, ELISA kits and recombinant proteins provide the initial commercial base for a broader research supply platform.
Build stronger conversion, institutional procurement routes and category depth around verified research needs.
Turn provider, product and evidence data into a durable advantage across discovery, evaluation and procurement.
We are particularly interested in partners who can accelerate life science marketplace growth, scientific data infrastructure, validation capability, institutional procurement, supplier development or international distribution. If that intersects with your investment thesis or strategic remit, we should talk.
Start the conversation
We welcome conversations with investors and strategic partners who understand marketplaces, life science, scientific data, validation or international distribution.